Sudden death risk in mitral valve prolapse using MRI and blood biomarkers
Official title: Sudden Death Risk Assessment and Mechanistic Insights in Arrhythmic Mitral Valve Prolapse Using Cardiac MRI and Circulating Proteomic Biomarkers
Funded at Methodist Hospital Research Institute · NIH-11362680 · Data updated 2026-11-12
A study in people with mitral valve prolapse will look for clues in MRI scans and blood markers to identify who might be at higher risk of sudden cardiac events.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,833,388 |
| NIH project number | 5R01HL171150-03 |
| Project ID | NIH-11362680 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with diagnosed mitral valve prolapse who consent to MRI, blood tests, and follow-up.
✕Less likely to help
Patients without MVP or who cannot undergo MRI or blood biomarker testing may not benefit.
What this research studies
This project will recruit MVP patients and use advanced cardiac MRI to search for heart changes linked to dangerous rhythms. It will also test a panel of blood biomarkers, including proteomic markers, to flag those at risk of scarring in the heart. Researchers aim to combine imaging and blood data to create a new risk prediction model for sudden death in MVP. The work follows NIH guidance to better identify at‑risk individuals and guide future care. The study is led by the Methodist Hospital Research Institute in Houston under an established NIH grant.
Why it matters
Potential benefit: If successful, the model could help doctors identify MVP patients who may need closer monitoring or preventive strategies to reduce sudden death risk.
How similar studies have gone: Prior research suggests a link between MVP-related arrhythmias and identifiable biomarkers or imaging changes, but a validated risk model remains to be established.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Shah, Dipan J. — Methodist Hospital Research Institute
- Study coordinator: Shah, Dipan J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.